Trial Profile
A Pharmacokinetic Study of DE-117 Ophthalmic Solution in Healthy Adult Male Subjects - Phase I Study -
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Sep 2020
Price :
$35
*
At a glance
- Drugs Omidenepag isopropyl (Primary)
- Indications Glaucoma; Ocular hypertension
- Focus Pharmacokinetics
- Sponsors Santen Pharmaceutical
- 28 Jun 2016 Status changed from active, no longer recruiting to completed.
- 08 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Feb 2016 New trial record